Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Featured Story from MarketBeat.com The Often-Missed Corner of Healthcare That Wall Street Is LovingBy Nathan Reiff. Publication Date: 3/29/2026. 
Key Points - Numerous lab equipment stocks are down in the high-teens so far this year, but seemingly modest sales growth may hide fundamental strengths.
- These companies can present a more secure approach to the healthcare industry than some higher-risk alternatives.
- Still, headwinds including tariff impacts and inflation remain a concern.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
The healthcare industry is notoriously volatile—company fortunes can be made or broken on the success of a single product or the results of a clinical trial—and it's not uncommon for stocks in the sector to post some of the market's largest spikes and drops. Investors who want exposure to the healthcare space but are wary of that volatility may prefer a "picks and shovels" approach, focusing on companies that provide essential equipment and services rather than higher-risk pharmaceutical names. Lab equipment stocks are often overlooked, even though several companies in this subindustry rank among the largest in healthcare. Given the external factors that could shape healthcare in 2026—shifting subsidies, an aging population, inflation, the growing role of AI, and more—core lab-equipment names may look more attractive. Below are several major players worth a closer look. A Recent Dip Masks Thermo Fisher's Long-Term Strengths Musk just launched another batch. Bezos secured approval for 50,000 more satellites. Right now, over 15,000 are circling the planet - and that number could triple by next year. The official story is global internet coverage. But a new presentation argues the real implications reach far beyond connectivity - and could change how the market works. Watch the presentation and see what the satellite race really means $182-billion life-sciences solutions, diagnostics, and analytical-instruments company Thermo Fisher Scientific (NYSE: TMO) has had a difficult start to 2026, with shares down more than 15% year-to-date (YTD). The company recently slipped into TradeSmith's red zone for financial health, and pressures such as tariffs and FX volatility cut margins by more than 100 basis points in 2025. Still, there are bright spots in Thermo Fisher's recent performance. In Q4 2025, revenue rose 7% year-over-year to $12.2 billion, beating analyst estimates by roughly $250 million. Adjusted earnings per share (EPS) also topped expectations at $6.57. That momentum may reflect several recent product launches, including the Orbitrap Astral Zoom mass spectrometer and new bioreactor products. Thermo Fisher's diversified business model could provide a cushion against external headwinds. Even if 2026 guidance is modest—revenue is forecast to grow 4% to 6%—improving EBITDA margins and steady customer demand offer support. Analysts remain largely positive: 17 of 19 rate the stock a Buy or equivalent, and consensus estimates imply more than 29% upside. Danaher's Business May Be Improving, Even as Guidance Remains Modest Danaher Corp. (NYSE: DHR) shares are down nearly 20% YTD, putting the instruments, consumables, and reagents company in a similar spot to Thermo Fisher. Although 2026 guidance calls for modest core revenue growth of 3% to 6% year-over-year, the most recent quarter showed a top- and bottom-line beat, and Danaher generated $5.3 billion in free cash flow for 2025. Two areas to watch in 2026 are Danaher's bioprocessing business, which is expected to deliver high-single-digit revenue growth driven by strong monoclonal-antibody demand, and diagnostics. Diagnostics should benefit from recent FDA clearances, and equipment orders have begun to improve after a prolonged weak period—both trends that could help sales recover. Analysts are reasonably upbeat on DHR, forecasting about 12.3% earnings growth over the next year and roughly 35% potential share-price appreciation. That optimism is reflected in ratings: 19 of 22 analysts currently rate Danaher shares a Buy. Agilent's Biocare Purchase Could Be a Catalyst Agilent Technologies (NYSE: A) lagged the peers above in its latest earnings, posting 4.4% year-over-year revenue growth and narrowly missing analyst expectations on both revenue and earnings. However, Agilent's recent acquisition of Biocare Medical could provide a meaningful growth driver by strengthening its position in cancer diagnostics. Although the deal cost nearly $1 billion, Biocare adds a recurring-revenue stream in a growing area. Cancer diagnostics can also carry higher margins than some of Agilent's existing lines, which could help expand operating margins (Agilent's operating margin was 24.6% in the most recent quarter). Shares are down about 17% YTD, but analysts see substantial upside—around 42%—and Wall Street classifies Agilent as a Moderate Buy, with 13 of 16 ratings at Buy or similar. | 
